Sutter Raoul, Kaplan Peter W
Clinic for Intensive Care Medicine, University Hospital Basel, Switzerland; Division of Clinical Neurophysiology, Department of Neurology, University Hospital Basel, Basel, Switzerland.
Department of Neurology, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
Epilepsy Behav. 2015 Aug;49:294-7. doi: 10.1016/j.yebeh.2015.02.044. Epub 2015 Mar 25.
Status epilepticus refractory to first-line and second-line antiepileptic treatments challenges neurologists and intensivists as mortality increases with treatment refractoriness and seizure duration. International guidelines advocate anesthetic drugs, such as continuously administered high-dose midazolam, propofol, and barbiturates, for the induction of therapeutic coma in patients with treatment-refractory status epilepticus. The seizure-suppressing effect of anesthetic drugs is believed to be so strong that some experts recommend using them after benzodiazepines have failed. Although the rationale for the use of anesthetic drugs in patients with treatment-refractory status epilepticus seems clear, the recommendation of their use in treating status epilepticus is based on expert opinions rather than on strong evidence. Randomized trials in this context are lacking, and recent studies provide disturbing results, as the administration of anesthetics was associated with poor outcome independent of possible confounders. This calls for caution in the straightforward use of anesthetics in treating status epilepticus. However, there are still more questions than answers, and current evidence for the adverse effects of anesthetic drugs in patients with status epilepticus remains too limited to advocate a change of treatment algorithms. In this overview, the rationale and the conflicting clinical implications of anesthetic drugs in patients with treatment-refractory status epilepticus are discussed, and remaining questions are elaborated. This article is part of a Special Issue entitled "Status Epilepticus".
对一线和二线抗癫痫治疗无效的癫痫持续状态给神经科医生和重症监护医生带来了挑战,因为随着治疗难治性和癫痫发作持续时间的增加,死亡率也会上升。国际指南提倡使用麻醉药物,如持续给予高剂量咪达唑仑、丙泊酚和巴比妥类药物,用于诱导治疗难治性癫痫持续状态患者进入治疗性昏迷。麻醉药物的抗癫痫作用被认为非常强大,以至于一些专家建议在苯二氮䓬类药物无效后使用它们。尽管在治疗难治性癫痫持续状态患者中使用麻醉药物的基本原理似乎很明确,但关于其用于治疗癫痫持续状态的建议是基于专家意见而非有力证据。在这方面缺乏随机试验,最近的研究给出了令人不安的结果,因为麻醉药物的使用与不良预后相关,且与可能的混杂因素无关。这就要求在直接使用麻醉药物治疗癫痫持续状态时要谨慎。然而,问题仍然多于答案,目前关于麻醉药物对癫痫持续状态患者不良反应的证据仍然过于有限,无法支持改变治疗方案。在本综述中,讨论了麻醉药物在治疗难治性癫痫持续状态患者中的基本原理和相互矛盾的临床意义,并阐述了尚存的问题。本文是名为“癫痫持续状态”的特刊的一部分。